$12.37
+0.19 (+1.56%)
Open$12.04
Previous Close$12.18
Day High$12.53
Day Low$11.92
52W High$12.48
52W Low$1.16
Volume—
Avg Volume1.36M
Market Cap655.66M
P/E Ratio—
EPS$-0.78
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+111.1% upside
Current
$12.37
$12.37
Target
$26.11
$26.11
$17.52
$26.11 avg
$31.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 93.03M | 87.17M | 93.25M |
| Net Income | -25,402,018 | -21,372,578 | -19,024,947 |
| Profit Margin | -27.3% | -24.5% | -20.4% |
| EBITDA | -33,224,495 | -30,585,289 | -30,503,356 |
| Free Cash Flow | -14,578,727 | -14,999,377 | -17,296,703 |
| Rev Growth | -8.3% | +13.0% | +19.4% |
| Debt/Equity | 0.78 | 0.63 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |